Spots Global Cancer Trial Database for navtemadlin
Every month we try and update this database with for navtemadlin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TL-895 and KRT-232 Study in Acute Myeloid Leukemia | NCT04669067 | Acute Myeloid L... | TL-895 KRT-232 | 18 Years - | Telios Pharma, Inc. | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia | NCT04835584 | Chronic Myeloid... | KRT-232 Dasatinib Nilotinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer | NCT03107780 | Glioblastoma Gliosarcoma MGMT-Unmethylat... Recurrent Gliob... | Biospecimen Col... Magnetic Resona... Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib | NCT04485260 | Myelofibrosis | KRT-232 Ruxolitinib | 18 Years - 99 Years | Kartos Therapeutics, Inc. | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | NCT03031730 | Plasmacytoma Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin | 18 Years - | National Cancer Institute (NCI) | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer | NCT05027867 | Small-cell Lung... Small Cell Lung... Small Cell Lung... Small Cell Lung... | KRT-232 | 18 Years - | Kartos Therapeutics, Inc. | |
| Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma | NCT03217266 | Resectable Soft... Soft Tissue Sar... | Navtemadlin Radiation Thera... | 18 Years - | National Cancer Institute (NCI) | |
| KRT-232 and TKI Study in Chronic Myeloid Leukemia | NCT04835584 | Chronic Myeloid... | KRT-232 Dasatinib Nilotinib | 18 Years - | Kartos Therapeutics, Inc. | |
| KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment | NCT03662126 | Primary Myelofi... Post-Polycythem... Post-Essential ... | KRT-232 Best Available ... | 18 Years - | Kartos Therapeutics, Inc. | |
| Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer | NCT05705466 | Non Small Cell ... | Navtemadlin Navtemadlin Pla... Pembrolizumab | 18 Years - | Kartos Therapeutics, Inc. | |
| Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | NCT03031730 | Plasmacytoma Recurrent Multi... Refractory Mult... | Biospecimen Col... Bone Marrow Asp... Carfilzomib Dexamethasone Dexamethasone S... Echocardiograph... Lenalidomide Navtemadlin | 18 Years - | National Cancer Institute (NCI) | |
| Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis | NCT04878003 | Primary Myelofi... Post-Polycythem... Post-Essential ... | KRT-232 TL-895 | 18 Years - | Kartos Therapeutics, Inc. | |
| Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia | NCT03041688 | Acute Myeloid L... Recurrent Acute... Refractory Acut... Secondary Acute... | Biospecimen Col... Bone Marrow Asp... Bone Marrow Bio... Decitabine Navtemadlin Venetoclax | 18 Years - | National Cancer Institute (NCI) | |
| Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL | NCT04502394 | Diffuse Large B... Chronic Lymphoc... Non Hodgkin Lym... | KRT-232 acalabrutinib | 18 Years - | Kartos Therapeutics, Inc. | |
| Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | NCT05797831 | Endometrial Can... | Navtemadlin Navtemadlin Pla... | 18 Years - | Kartos Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
